ライフサイエンスコーパス: TCID50

1 ectious virus produced by RPE cells (10(6.5) TCID50/0.1 ml) significantly surpassed levels produced b

2 rpassed levels produced by HEL cells (10(5.5)TCID50/0.1 ml).

3 han when given at the regular dose, 10(7.26) TCID50 (40 participants); as a control, a placebo vaccin

4 ncentrations ranging from 10(1.4) to 10(4.4) TCID50/5 microliters were capable of inducing both infla

5 the highest concentration of virus (10(4.4) TCID50/5 microliters) in CD-1 mice resulted in only the

6 CTL response when given at a dose of 10(8.0) TCID50 (60 participants) than when given at the regular

7 from 0.01 50% tissue culture infective dose (TCID50) and were able to detect at least 1 TCID50 of ent

8 nts treated at high-dose levels (10(8)-10(9) TCID50), and their median overall survival of 26.5 month

9 determined by RT-qPCR and virion release by TCID50 assay.

10 8 (HHV-8) 50% tissue culture infective dose (TCID50) assay using the T1H6-DC-SIGN cell line.

11 HRV (1-10 TCID50/cell) significantly inhibited T cell proliferatio

12 to 10(9) 50% tissue culture infective doses (TCID50) consistently infected all the animals, and many

13 s, and many monkeys receiving 10(8) or 10(9) TCID50 developed paralysis.

14 ction of immature dendritic cells at various TCID50 doses.

15 immunodeficiency virus type 1 (HIV-1) and <1 TCID50 for simian immunodeficiency virus isolated from a

16 ml in the blood and between 10(6) and 10(10) TCID50/g tissue in the intestines, kidney, lungs, brain,

17 .5 log10 50% tissue culture infectious dose [TCID50]) in nasal wash viral titers and inflammation res

18 Viral antigen-specific ELISAs, qRT-PCR and TCID50 infectious assays were utilized to determine anti

19 166) were inoculated intranasally with 10(5) TCID50 influenza A/Texas/91 (H1N1) virus.

20 a-galactosidase, which was used to determine TCID50 levels.

21 ingle high doses ranging from 10(7) to 10(9) TCID50 Mahoney type 1 virus were infected, and many of t

22 urine blood (EBOV concentration of 1 x 10(7) TCID50 . ml(-1)) at 4:1 vol/vol buffer/sample ratios.

23 issue culture infective dose per milliliter [TCID50 . ml(-1)]) and murine blood (EBOV concentration o

24 x 10(-3) 50% tissue culture infective doses (TCID50)/ml of cultured MERS-CoV per reaction.

25 4 x 10(2) 50% tissue culture infective dose (TCID50)/ml, as well as the no-virus negative-control sam

26 x 10(5) 50% tissue culture infective doses (TCID50)/ml.

27 Virus titers reached 10(8) TCID50/ml in the blood and between 10(6) and 10(10) TCID

28 50/mL, for a saturation value of ~4.801x10(3)TCID50/mL, with good repeatability and excellent specifi

29 tive results, was determined to be 4 x 10(2) TCID50/ml.

30 Three doses of 106.5 TCID50 of ALVAC-CMV(gB) induced very low neutralizing or

31 gative adults randomly received either 106.8 TCID50 of ALVAC-CMV(gB) or 106.8 TCID50 of ALVAC-RG, exp

32 ) vector expressing HIV-1MN gp160 or 10(5.5) TCID50 of ALVAC-rabies virus glycoprotein control at 0 a

33 ither 106.8 TCID50 of ALVAC-CMV(gB) or 106.8 TCID50 of ALVAC-RG, expressing the rabies glycoprotein,

34 tion against experimental challenge with 107 TCID50 of attenuated H1N1 (vaccine strain) by intranasal

35 Two doses of 10(7) TCID50 of ca influenza virus infected all infants, indic

36 ho were randomized to receive 10(6) or 10(7) TCID50 of canarypox (ALVAC) vector expressing HIV-1MN gp

37 (TCID50) and were able to detect at least 1 TCID50 of enterovirus in cerebrospinal fluid, stool, or

38 nuclear cells (PBMC) were challenged with 10 TCID50 of HIV-1MN or HIV-1BaL, titered in PBMC from norm

39 ety and immunogenicity of two doses of 10(7) TCID50 of live, attenuated cold-adapted (ca) influenza A

40 D50) of virus were estimated to be <1 and 10 TCID50 of MERS-CoV, respectively.

41 These data support the use of 10(8) TCID50 of MVA-BN in this population.

42 0 subjects received vaccine containing 10(8) TCID50 of MVA-BN, and 4 subjects received placebo.

43 by intraperitoneal (i.p.) injection of 10(5) TCID50 of SHRV/ml.

44 s received a single intranasal dose (10(6.2) TCID50) of ca A/Kawasaki/9/86 (H1N1) or ca A/Los Angeles

45 10(7) median tissue culture infective doses (TCID50) of MVA-BN, 10 subjects received vaccine containi

46 in 10(6) 50% tissue culture infective doses (TCID50) of SHRV/ml, and adult zebrafish were susceptible

47 ID50) per 0.05 mL], medium dose [7.5 x 10(4) TCID50 per 0.25 mL], or high dose [3.0 x 10(5) TCID50 pe

48 ID50 per 0.25 mL], or high dose [3.0 x 10(5) TCID50 per 1.0 mL]), or the active comparator-Priorix.

49 10(4) median tissue culture infection doses (TCID50) per 0.05 mL], medium dose [7.5 x 10(4) TCID50 pe

50 hy and 11 atopic asthmatic adults with 2,000 TCID50 RV-16.

51 l dose (LD50) was determined to be 0.015 50% TCID50 (tissue culture infective dose) of MARV/Ang-MA in

52 ybrid microchips was determined to be ~10(4) TCID50 titer/mL and 10(3)-10(4) EID50 titer/mL.

53 Validation of TCID50 values was performed by immunofluorescence assay

54 x 10(-2) 50% tissue culture infective doses (TCID50), was developed.